New study aims to predict lung damage from cancer treatments before It's too late
NCT ID NCT07190703
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks for early warning signs of lung injury caused by cancer drugs. Researchers will analyze blood and lung fluid samples from 200 patients using advanced techniques to find biomarkers that could predict or detect this side effect early. The goal is to help doctors identify at-risk patients sooner and improve treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood or fluid test that catches lung damage from cancer drugs early, helping doctors adjust treatment sooner.
- What could go wrong
- This is an observational study, not testing a treatment. It is early-stage research, and the biomarkers may not prove reliable in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-TUMOR DRUG-ASSOCIATED INTERSTITIAL PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.